Phase III STaMINA Trial: Similar PFS With Single ASCT, Single ASCT Followed by RVD Consolidation, and Tandem ASCT in Frontline MM Treatment

December 3-6, 2016; San Diego, California
After current standard-of-care induction therapy for newly diagnosed MM, similar survival outcomes seen with single ASCT and maintenance lenalidomide with or without additional RVD consolidation or tandem ASCT even in patients with high-risk disease.
Format: Microsoft PowerPoint (.ppt)
File Size: 629 KB
Released: December 9, 2016

Acknowledgements

This activity is supported by educational grants from
Amgen
Celgene Corporation
Incyte
Merck & Co., Inc.
Seattle Genetics

Related Content

Downloadable slideset of FcRn pathway inhibition in patients with ITP, from Clinical Care Options (CCO)

David J. Kuter, MD, DPhil Released: July 23, 2021

Downloadable slideset of BTK inhibitors in patients with ITP, from Clinical Care Options (CCO)

David J. Kuter, MD, DPhil Released: July 23, 2021

Downloadable slideset of an expert’s overview of emerging therapies for patients with ITP, from Clinical Care Options (CCO)

David J. Kuter, MD, DPhil Released: July 23, 2021

Downloadable slideset of complement inhibition in patients with ITP, from Clinical Care Options (CCO)

person default Catherine M. Broome, MD Released: July 23, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue